A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.
Scardino, Antonio;
Alimandi, Maurizio;
Correale, Pierpaolo;
Smith, Steven G;
Bei, Roberto;
Firat, Hüseyin;
Cusi, Maria Grazia;
Faure, Olivier;
Graf-Dubois, Stephanie;
Cencioni, Giulia;
+5 more...Marrocco, Jordan;
Chouaib, Salem;
Lemonnier, François A;
Jackson, Andrew Michael;
Kosmatopoulos, Kostas;
(2007)
A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.
Cancer research, 67 (14).
pp. 7028-7036.
ISSN 0008-5472
DOI: https://doi.org/10.1158/0008-5472.CAN-06-3998
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
A cDNA vaccine (pVax1/pet-neu) was designed to encode 12 different Her-2/ErbB-2-derived, HLA-A*0201-restricted dominant and high-affinity heteroclitic cryptic epitopes. Vaccination with pVax1/pet-neu triggered multiple and ErbB-2-specific CTL responses in HLA-A*0201 transgenic HHD mice and in HLA-A*0201 healthy donors in vitro. Human and murine CTL specific for each one of the 12 ErbB-2 peptides recognized in vitro both human and murine tumor cells overexpressing endogenous ErbB-2. Furthermore, vaccination of HHD mice with pVax1/pet-neu significantly delayed the in vivo growth of challenged ErbB-2-expressing tumor (EL4/HHD/neu murine thymoma) more actively when compared with vaccination with the empty vector (pVax1) or vehicle alone. These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2-specific antitumor responses against dominant and cryptic multiple epitopes.